首頁 > 市場調查報告書 > 醫療設備

整形外科

市場調查報告書

商品編碼

1738851

軟組織修復市場：人口統計、軟組織損傷類型、治療方法和地區，2026-2032 年

Soft Tissue Repair Market By Demography, Type of Soft Tissue Injury, Methods of Treatment, & Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年軟組織修復市場評估

運動傷害的增加和人口老化推動了外科手術和修復產品的需求。此外，人們對微創手術技術的認知不斷提高，也鼓勵更多患者選擇這些手術，加速市場成長，預計2024年將達到194.7億美元，到2032年將達到291.3億美元。

醫療技術的進步，例如新型縫合線、移植物和固定裝置的開發，正在提高軟組織手術的功效和結果，從 2026 年到 2032 年，複合年成長率約為 5.17%。

軟組織修復市場定義/概述

軟組織修復包括手術和非手術手段，旨在恢復受損軟組織（例如肌肉、肌腱、韌帶和筋膜）的完整性和功能。運動醫學和整形外科手術，以及重組手術和創傷治療，均用於治療各種損傷和疾病。隨著生物材料、再生醫學和微創手術的進步，癒合效果得以改善，恢復時間得以縮短，軟組織修復的未來前景一片光明。此外，智慧技術與個體化醫療相結合，有望實現個人化治療，從而增強軟組織修復在臨床實踐中的潛力。

人們對微創手術技術的認知不斷提高是否會推動軟組織修復市場的發展？

人們對微創手術 (MIS) 的認知和利用日益成長，正在大力推動軟組織修復市場向前發展。根據美國微創外科學會 (ASMIS) 的數據，2024 年用於軟組織修復的 MIS 手術將比 2022 年增加 42%，僅在北美就將進行超過 850 萬例手術。 2024 年 2 月，國際關節鏡、膝關節外科和整形外科運動醫學學會宣布，目前全球 73% 的軟組織手術採用微創手術，高於 2022 年 2 月的 58%。此外，世界衛生組織 (WHO) 在 2024 年 3 月發布的統計數據顯示，與傳統開放性手術相比，MIS 手術可將恢復時間縮短 65%，住院時間縮短 48%。

2024年1月，強生公司的DePuy Synthes宣布將投資8億美元開發下一代微創軟組織修復技術，先前其MIS部門的收益成長了38%。 2024年3月，Medtronic推出了其先進的關節鏡修復系統，稱其微創手術器械部門的收入與前一年同期比較成長了45%。 2024年2月，歐盟醫療創新舉措投入3.2億歐元，用於推動軟組織修復領域的MIS技術。此外，波士頓科學公司在2024年12月宣布，其微創軟組織修復產品線的全球銷售額成長了52%。 2024年3月，中國國家衛生健康委員會宣布了一項全面的醫療現代化計畫，投資23億美元用於推廣微創手術技術，並設定了到2026年將MIS手術增加40%的目標。

不斷增加的監管障礙是否會阻礙軟組織修復市場的成長？

日益嚴格的監管限制會延長產品開發和核准時間，嚴重限制軟性組織修復產業的發展。監管機構的嚴格標準，例如嚴格的臨床試驗和詳細的安全評估，導致新產品上市延遲。這不僅抬高了製造商的價格，也阻礙了那些無力應對複雜監管流程的小型企業的發展，從而扼殺了創新並降低了市場競爭力。

此外，法規的不斷變化，尤其是在再生醫學這樣的新興產業，也為企業帶來了額外的不確定性。由於需要不斷適應新的要求，遵循成本可能會抑制投資，阻礙新技術的採用。結果，治療方案的改善速度變慢，對患者的治療效果產生負面影響，並限制了軟組織修復市場的整體成長潛力。

The increased prevalence of sports-related injuries, combined with an aging population, is boosting demand for surgical procedures and repair products. Furthermore, increasing awareness of minimally invasive surgical techniques encourages more patients to choose these operations, accelerating market growth is fueling USD 19.47 Billion in 2024 and reaching USD 29.13 Billion by 2032.

Advances in medical technology, such as the creation of novel sutures, grafts, and fixation devices, are improving the efficacy and results of soft tissue procedures is grow at a CAGR of about 5.17% from 2026 to 2032

Soft Tissue Repair Market: Definition/ Overview

Soft tissue repair encompasses both surgical and non-surgical procedures for repairing the integrity and function of damaged soft tissues, such as muscles, tendons, ligaments, and fascia. Sports medicine and orthopedic surgery, as well as reconstructive procedures and wound healing, are all used to treat a wide range of injuries and ailments. The future of soft tissue repair seems optimistic, with advances in biomaterials, regenerative medicine, and minimally invasive procedures ready to improve healing results and shorten recovery periods. Furthermore, the combination of smart technologies and customized medicine may result in tailored treatments, increasing the potential of soft tissue restoration in clinical practice.

Will Increasing Awareness of Minimally Invasive Surgical Techniques Propel the Soft Tissue Repair Market?

The increasing awareness and use of minimally invasive surgical (MIS) procedures is considerably propelling the soft tissue repair market forward. According to the American Society for Minimally Invasive Surgery (ASMIS), the use of MIS operations for soft tissue repair grew by 42% in 2024 compared to 2022, with over 8.5 million treatments conducted in North America alone. In February 2024, the International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine announced that 73% of all soft tissue surgeries worldwide now use minimally invasive procedures, up from 58% in February 2022. Furthermore, the World Health Organization (WHO) published statistics in March 2024 demonstrating that MIS operations save recovery time by 65% and hospital stays by 48% compared with to traditional open surgeries.

In January 2024 Johnson & Johnson's DePuy Synthes announced a USD 800 Million investment in developing next-generation minimally invasive soft tissue repair technologies, following a 38% growth in MIS division revenue. Medtronic released their advanced arthroscopic repair system in March 2024, citing a 45% year-over-year increase in the minimally invasive surgical instruments segment. In February 2024, the European Union's Healthcare Innovation Initiative committed €320 million to advance MIS technologies in soft tissue restoration. Furthermore, Boston Scientific stated in December 2024 that their minimally invasive soft tissue repair product line saw a 52% increase in global sales. In March 2024, the Chinese National Health Commission unveiled a comprehensive healthcare modernization plan, investing $2.3 billion in promoting minimally invasive surgical methods, with a goal of increasing MIS procedures by 40% by 2026.

Will Growing Regulatory Hurdles Hinder the Growth of the Soft Tissue Repair Market?

Growing regulatory constraints can significantly restrict the soft tissue repair industry by lengthening product development and approval times. Regulatory bodies' stringent standards, such as rigorous clinical trials and detailed safety assessments, can cause delays in the marketing of novel products. This not only raises prices for manufacturers, but it also inhibits smaller businesses that may lack the means to negotiate complex regulatory processes, thus suffocating innovation and decreasing market competitiveness.

Furthermore, the continually changing nature of rules, particularly in new industries such as regenerative medicine, creates further uncertainty for businesses. Because they must constantly adjust to new requirements, compliance expenses can discourage investment and hinder the adoption of new technologies. As a result, treatment choices evolve at a slower rate, which can have a negative impact on patient outcomes and limit the soft tissue repair market's total growth potential.

Category-Wise Acumens

Will Rising Incidence of Sports Injuries Propel the Soft Tissue Repair Market?

The rising frequency of sports injuries is expected to considerably propel the soft tissue repair market, owing to increased participation in sports and recreational activities among all age groups. As more people participate in high-impact sports, the demand for effective treatment alternatives for injuries such ligament tears, tendonitis, and muscular strains increases. According to recent projections, the worldwide sports medicine industry, which includes soft tissue repair, is predicted to reach USD 9.7 Billion by 2025, demonstrating the growing demand for new repair options. Companies such as Medtronic and Johnson & Johnson are aggressively developing new surgical devices and biologics to treat these injuries, which is driving market growth.

Furthermore, government attempts to promote sports and physical activity may contribute to this growing tendency. For instance, in March 2024, the United States government launched a new plan to encourage youth sports participation, including funding for sports programs and injury prevention education. Such efforts not only inspire more individuals to participate in sports, but they also raise the probability of injuries, driving up demand for soft tissue repair solutions. This combination of increased sports involvement and improved treatment choices sets the soft tissue repair industry for strong growth in the next years.

However, the fastest-growing group is degenerative ailments, which are being driven by an aging population and an increasing prevalence of chronic diseases like osteoarthritis. As people become more aware of treatment alternatives for illnesses like tendinitis and ligament tears, this area is likely to grow quickly. Traumatic injuries continue to be a substantial market segment, but their growth rate is slower than that of degenerative illnesses, which are gaining recognition in both the clinical and patient populations.

Will Rising Aging Population Fuel the Soft Tissue Repair Market?

The aging population is likely to drive the soft tissue repair market, as older persons are more prone to degenerative disorders and injuries that require repair interventions. Age-related conditions, such as tendon deterioration and joint difficulties, may necessitate surgical interventions for effective therapy. In April 2024According to a World Health Organization research released, the global population aged 65 and older is expected to quadruple by 2050, indicating an increased demand for medical interventions, including soft tissue repair solutions. Companies such as Stryker and Zimmer Biomet are actively extending their product lines to cater to this demographic, with an emphasis on breakthrough surgical procedures and materials that improve recovery in older patients.

Additionally, government measures targeted at addressing the healthcare needs of the aging population contribute to market growth. In January 2024, the United States Department of Health and Human treatments unveiled a new framework for enhancing older individuals' access to healthcare, which includes increased financing for orthopedic and rehabilitation treatments. This emphasis on geriatric care not only highlights the importance of effective soft tissue repair choices, but it also pushes industry companies to engage in R&D. The soft tissue repair market is expected to increase significantly in the future years as demand for therapies rises in tandem with the aging population.

Young adults, particularly those who participate in sports and fitness activities, are the fastest-growing group. This surge is being driven by increased sports involvement and a growing awareness of injuries among young people. Furthermore, socioeconomic status is important, with higher-income persons often having greater access to modern treatment alternatives.

Country/Region-wise

Will Rising Investment In Medical Technology in North America Drive the Soft Tissue Repair Market?

The growing investment in medical technology in North America is significantly driving the growth of the soft tissue repair market, with significant funds moving into research, development, and commercialization of improved treatment solutions. According to the Medical Device Innovation Consortium (MDIC), North American investment in medical technology will reach USD 52.4 Billion by 2024, with soft tissue repair technologies accounting for USD 7.8 Billion. In February 2024, the American Association of Tissue Banks stated that demand for soft tissue allografts climbed by 34% in 2024 compared to 2022. In March 2024, the US Centers for Medicare & Medicaid Services (CMS) announced that reimbursement coverage for minimally invasive soft tissue operations increased by 28% in 2024, with approved procedures rising from 2,800 to 3,584.

In January 2024, Smith & Nephew announced a $600 million investment in its Tennessee factory to enhance production of innovative soft tissue repair devices, following a 42% growth in sports medicine division revenue. In March 2024, Arthrex announced a new USD 450 Million research facility in Florida dedicated to soft tissue repair technologies, with plans to create 1,200 specialist jobs. In February 2024, the US National Institutes of Health (NIH) launched a USD 275 Million grant program for soft tissue repair research activities. In March 2024 while Zimmer Biomet received FDA approval for their innovative biological scaffold technology, which is supported by a USD 300 Million investment in R&D.

Will Increasing Healthcare Expenditure in Asia Pacific Propel the Soft Tissue Repair Market?

Increasing healthcare spending in Asia-Pacific is expected to significantly boost the soft tissue repair market. As countries in this region continue to invest in healthcare infrastructure and access to new medical technologies, there is an increasing demand for effective soft tissue injury treatments. For instance, In March 2024 the Asian Development Bank stated that healthcare spending in Asia-Pacific is expected to exceed USD 1 Trillion by 2025, driven by a growing middle class and increased awareness of health issues. Companies such as Medtronic and Arthrex are growing their position in this market by introducing novel products that are suited to the region's unique needs.

Furthermore, government actions to improve healthcare access boost market growth. In July 2024, the Indian government announced the "Health Systems for a New India" project, which includes aims to improve orthopedic and rehabilitation care. This program not only demonstrates the dedication to improving healthcare, but it also presents chances for companies who specialize in soft tissue healing. As healthcare costs rise and more resources are committed to treating soft tissue injuries and diseases, the market in Asia-Pacific is predicted to grow significantly.

Competitive Landscape

The competitive landscape of the soft tissue repair market is characterized by a mix of established companies and emerging players focusing on innovation and specialization. Companies are increasingly investing in research and development to introduce advanced biomaterials, minimally invasive techniques, and regenerative medicine approaches, enhancing treatment outcomes. Strategic partnerships, mergers, and acquisitions are common as firms seek to expand their product portfolios and geographical reach. Additionally, there is a growing emphasis on personalized medicine, which is shaping product development and marketing strategies. The market is also influenced by regulatory factors, reimbursement policies, and changing patient demographics, prompting companies to adapt their approaches to stay competitive and meet evolving consumer needs.

Some of the prominent players operating in the soft tissue repair market Include:

Johnson & Johnson

Smith & Nephew plc

Medtronic plc

Stryker Corporation

Integra LifeSciences Corporation

Acelity L.P., Inc.

Arthrex, Inc.

Zimmer Biomet Holdings, Inc.

Olympus Corporation

Boston Scientific Corporation

Latest Developments

In February 2024, Smith & Nephew introduced a new line of sophisticated wound care solutions that contain soft tissue repair components. These products aim to improve patient outcomes by enhancing moisture management and infection control, which aligns with the growing demand for comprehensive wound treatment solutions.

In April 2024, Baxter stated that it was developing a unique biologic scaffold for soft tissue regeneration. This medication is intended to enhance healing and tissue regeneration, meeting an important need in difficult soft tissue repair instances.